Interstitial lung disease in systemic sclerosis: From immunopathogenesis to treatment

1 Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respiratory Research. 2019;20(1): 13. Search in Google Scholar

2 Schoenfeld SR, Castelino FV. Evaluation and management approaches for scleroderma lung disease. Therapeutic Advances in Respiratory Disease. 2017;11(8): 327–340. Search in Google Scholar

3 Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. The European Respiratory Review. 2013;22(127): 6–19. Search in Google Scholar

4 Mango R, Ryu J, Makol A. Newer insights into the management of interstitial lung disease in systemic sclerosis. Indian Journal of Rheumatology. 2107;12: S194–S203. Search in Google Scholar

5 Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmunity Reviews. 2011;10(5): 248–255. Search in Google Scholar

6 Luo Y, Xiao R. Interstitial lung disease in scleroderma: clinical features and pathogenesis. Rhematology. 2011;S1(2): 1–5. Search in Google Scholar

7 Jain S, Shahane A, Derk CT. Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy. Inflammation & Allergy-Drug Targets. 2012;11(4): 266–277. Search in Google Scholar

8 Akter T, Silver RM, Bogatkevich GS. Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease. Current Rheumatology Reports. 2014;16(4): 411. Search in Google Scholar

9 Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Aetiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med. 2020;201(6): 650–660. Search in Google Scholar

10 Cutolo M, Soldano S, Smith V. Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Review of Clinical Immunology. 2019;15(7): 753–764. Search in Google Scholar

11 Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, et al. Systemic sclerosis. Nature reviews. Disease Primers. 2015;1: 15002. Search in Google Scholar

12 Ahmed S, Pattanaik S, Rai M, Nath A, Agarwal V. Interstitial lung disease in systemic sclerosis: insight into pathogenesis and evolving therapies. Mediterranean Journal of Rheumatology. 2018;29(3): 140–147. Search in Google Scholar

13 Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Annals of the Rheumatic Diseases. 2015;74(6): 1188–1194. Search in Google Scholar

14 Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. The Lancet. RespiratoryMedicine. 2020;8(3): 304–320. Search in Google Scholar

15 Soldano S, Trombetta AC, Contini P, Tomatis V, Ruaro B, Brizzolara R, et al. Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis. Annals of the Rheumatic Diseases. 2018;77(12): 1842–1845. Search in Google Scholar

16 Trombetta AC, Soldano S, Contini P, Tomatis V, Ruaro B, Paolino S, et al. A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement. Respiratory Research. 2018;19(1): 186. Search in Google Scholar

17 Veraldi KL, Hsu E, Feghali-Bostwick CA. Pathogenesis of pulmonary fibrosis in systemic sclerosis: lessons from interstitial lung disease. Current Rheumatology Reports. 2010;12(1): 19–25. Search in Google Scholar

18 Volkmann ER, Tashkin DP. Treatment of systemic sclerosis- related interstitial lung disease: a review of existing and emerging therapies. Ann The American Thoracic Society. 2016;13(11): 2045–2056. Search in Google Scholar

19 Wells AU. Interstitial lung disease in systemic sclerosis. Presse Medicale. 2014;43(10 Pt 2): e329–e343. Search in Google Scholar

20 Chowaniec M, Skoczynska M, Sokolik R, Wiland P. Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management. Reumatologia 2018;56(4): 249–254. Search in Google Scholar

21 Cappelli S, Bellando Randone S, Camiciottoli G, De Paulis A, Guiducci S, Matucci-Cerinic M. Interstitial lung disease in systemic sclerosis: where do we stand? European Respiratory Review. 2015;24(137): 411–419. Search in Google Scholar

22 Branley H. Pulmonary fibrosis in systemic sclerosis: diagnosis and management. Respiratory Medicine CME. 2010;3: 10–14. Search in Google Scholar

23 Bonifazi M, Sverzellati N, Negri E, Jacob J, Egashira R, Moser J, et al. Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact. The European Respiratory Journal. 2020;56(1): 1902135. Search in Google Scholar

24 Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. American Journal of Respiratory and Critical Care Medicine. 2008;177(11): 1248–1254. Search in Google Scholar

25 Hoffmann-Vold A-M, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. The Lancet Rheumatology. 2020;2(2): e71–e83. Search in Google Scholar

26 Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. The New England Journal of Medicine. 2006;354(25): 2655–2666. Search in Google Scholar

27 Roofeh D, Distler O, Allanore Y, Denton CP, Khanna D. Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. Journal of Scleroderma and Related Disorders. 2020;5 (2 Suppl): 61–71. Search in Google Scholar

28 Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis & Rheumatology. 2006;54(12): 3962–3970. Search in Google Scholar

29 Ueda T, Sakagami T, Kikuchi T, Takada T. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis. Respiratory Investigation. 2018;56(1): 14–20. Search in Google Scholar

30 Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. The Lancet Respiratory Medicine. 2016;4(9): 708–719. Search in Google Scholar

31 Baqir M, Makol A, Osborn TG, Bartholmai BJ, Ryu JH. Mycophenolate mofetil for scleroderma-related interstitial lung disease: a real world experience. PLoS One. 2017;12(5): e0177107. Search in Google Scholar

32 Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. The New England Journal of Medicine. 2019;380(26): 2518–2528. Search in Google Scholar

33 Hayton C, Chaudhuri N. Current treatments in the management of idiopathic pulmonary fibrosis: pirfenidone and nintedanib. Clinical Medicine Insights: Therapeutics. 2017;9: 1–4. Search in Google Scholar

34 Acharya N, Sharma SK, Mishra D, Dhooria S, Dhir V, Jain S. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial. Rheumatol Int. 2020;40(5): 703–710. Search in Google Scholar

35 Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. The Journal of Rheumatology. 2016;43(9): 1672–1679. Search in Google Scholar

36 Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018;57(12): 2106–2113. Search in Google Scholar

37 Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038): 2630–2640. Search in Google Scholar

38 Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSS-cinate). Annals of the Rheumatic Diseases. 2018;77(2): 212–220. Search in Google Scholar

39 Narváez J, LLuch J, Alegre Sancho JJ, Molina-Molina M, Nolla JM, Castellví I. Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated inter-stitial lung disease: a case series. Annals of the Rheumatic Diseases. 2019;78(11): e123. Search in Google Scholar

40 van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24): 2490–2498. Search in Google Scholar

41 Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. The New England Journal of Medicine. 2018;378(1): 35–47. Search in Google Scholar

42 Chan EY, Goodarzi A, Sinha N, Nguyen DT, Youssef JG, Suarez EE, et al. Long-term survival in bilateral lung transplantation for scleroderma-related lung disease. The Annals of Thoracic Surgery. 2018;105(3): 893–900. Search in Google Scholar

43 Pradere P, Tudorache I, Magnusson J, Savale L, Brugiere O, Douvry B, et al. Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study. The Journal of Heart and Lung Transplantation. 2018;37(7): 903–911. Search in Google Scholar